Research
Hormonal
BGM0504, a GLP-1R/GIPR dual agonist with optimized acylation, demonstrates superior glycemic control, weight loss, and liver health improvements compared to Tirzepatide in diabetic and NASH mouse models.
BGM0504 is an experimental dual-agonist peptide designed to treat diabetes and obesity more effectively than existing drugs like Tirzepatide. In animal studies, it lowered blood sugar and body weight with fewer side effects on liver health. It is not yet available for human use.
ModerateSupportsLOW confidence
BGM0504 exhibited superior efficacy compared to Tirzepatide... BGM0504 effectively addresses diabetes combined with NASH, outperforming Tirzepatide at equivalent doses.
Why this rating
Animal models only; no human data.
Source
Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity
Jiandong Yuan et al. · Scientific Reports · 2024
DOI 10.1038/s41598-024-66998-8
mechanism_onlyCited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →